Immunology and Microbiology
Atopic Dermatitis
97%
Severe Acute Respiratory Syndrome Coronavirus 2
48%
Immune-Mediated Inflammatory Diseases
34%
Eczema
24%
Immunosuppressant
22%
Humoral Immunity
16%
T Cell
16%
Cytotoxic T-Cell
14%
Thymus and Activation Regulated Chemokine
14%
Breakthrough Infection
13%
Regulatory T Cell
13%
Seroconversion
13%
Staphylococcus Aureus
11%
Squamous Cell
11%
Interleukin 13
10%
TNF Inhibitor
10%
Ciclosporin
9%
CD20
9%
Immunosuppressive Drug
9%
Dupilumab
9%
Inflammatory Disorder
8%
Imiquimod
7%
Cytokine
6%
T-Helper Cell
6%
Multiple Sclerosis
6%
Immunoglobulin E
6%
Immune Response
6%
Cutaneous T Cell Attracting Chemokine
6%
Programmed Cell Death
5%
Omicron Coronavirus Variant
5%
Interleukin 17
5%
Antibody Titer
5%
Synovial Fluid
5%
Monoclonal Antibody
5%
T Cell Activation
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atopic Dermatitis
100%
Disease Activity
24%
Dupilumab
19%
Pruritus
19%
Biological Marker
19%
Inflammatory Disease
19%
SARS Coronavirus
18%
Adverse Event
15%
Upadacitinib
12%
Tralokinumab
11%
Immunosuppressive Agent
10%
Eczema
10%
Topical Corticosteroid
9%
Placebo
8%
Diseases
8%
Baricitinib
7%
Thymus and Activation Regulated Chemokine
7%
Cohort Study
6%
Infection
6%
Neurodermatitis
5%
Proteinase
5%
Randomized Controlled Trial
5%
Janus Kinase Inhibitor
5%
Monoclonal Antibody
5%
Medicine and Dentistry
Atopic Dermatitis
49%
Inflammatory Disorder
19%
COVID-19 Vaccination
13%
T Cell
11%
Squamous Cell Carcinoma
10%
Eczema
10%
Messenger RNA
9%
Dermatology
9%
Quality of Life
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
TNF Inhibitor
9%
Coronary Artery
9%
Biological Marker
9%
Disease Activity
8%
Imiquimod
7%
Diseases
7%
Neoplasm
7%
Adverse Event
6%
Immunosuppressive Drug
6%
Macrophage
6%
COVID-19
5%
Janus Kinase Inhibitor
5%
Pruritus
5%
Immunosuppressant
5%
Cohort Analysis
5%
Cytotoxic T-Cell
5%
